2025
IPWR Ideal Power Inc
NRSN Neurosense Therapeutics Ltd
ACNT Ascent Industries Co
FATH Fathom Digital Manufacturing Corp
PAYX Paychex Inc
WAVD Wavedancer Inc
RNXT RenovoRx Inc
GBNY Generations Bancorp NY Inc
POL Polished.Com Inc
Go

Health Care : Biotechnology | Small Cap Value

Cyclo Therapeutics, Inc. is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is a treatment for Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. It is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. Its product lines include Trappsol and Aquaplex. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The Company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors.

Price: Delayed
$0.37

Day's Change: 0.00 (0.00%)

Bid: --

Ask: --

B/A Size: --

Day's High: --

Day's Low: --

Volume (Average) Today's volume of 2,018 shares is on pace to be in-line with CYTHW's 10-day average volume of 2,018 shares.: 2,018

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.